vs
Playtika Holding Corp.（PLTK）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Playtika Holding Corp.的1.1倍（$772.1M vs $678.8M），Revvity净利率更高（12.7% vs -45.6%，领先58.3%），Revvity同比增速更快（5.9% vs 4.4%），Playtika Holding Corp.自由现金流更多（$275.2M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 2.1%）
Playtika Holding Corp是一家专注于移动端游戏开发与发行的以色列数字娱乐企业，主打休闲社交类手游产品，在全球拥有庞大用户群体。截至2021年，该公司月活跃用户规模已经突破3500万，是行业内影响力突出的移动游戏厂商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PLTK vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$678.8M
营收增速更快
RVTY
高出1.5%
4.4%
净利率更高
RVTY
高出58.3%
-45.6%
自由现金流更多
PLTK
多$113.4M
$161.8M
两年增速更快
RVTY
近两年复合增速
2.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $678.8M | $772.1M |
| 净利润 | $-309.3M | $98.4M |
| 毛利率 | 72.5% | — |
| 营业利润率 | -41.4% | 14.5% |
| 净利率 | -45.6% | 12.7% |
| 营收同比 | 4.4% | 5.9% |
| 净利润同比 | -1752.1% | 3.9% |
| 每股收益（稀释后） | $-0.83 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLTKRVTY
| Q4 25 | $678.8M | $772.1M | ||
| Q3 25 | $674.6M | $698.9M | ||
| Q2 25 | $696.0M | $720.3M | ||
| Q1 25 | $706.0M | $664.8M | ||
| Q4 24 | $650.3M | $729.4M | ||
| Q3 24 | $620.8M | $684.0M | ||
| Q2 24 | $627.0M | $691.7M | ||
| Q1 24 | $651.2M | $649.9M |
净利润PLTKRVTY
| Q4 25 | $-309.3M | $98.4M | ||
| Q3 25 | $39.1M | $46.7M | ||
| Q2 25 | $33.2M | $53.9M | ||
| Q1 25 | $30.6M | $42.2M | ||
| Q4 24 | $-16.7M | $94.6M | ||
| Q3 24 | $39.3M | $94.4M | ||
| Q2 24 | $86.6M | $55.4M | ||
| Q1 24 | $53.0M | $26.0M |
毛利率PLTKRVTY
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.6% | 53.6% | ||
| Q2 25 | 71.9% | 54.5% | ||
| Q1 25 | 72.0% | 56.5% | ||
| Q4 24 | 72.5% | — | ||
| Q3 24 | 72.9% | 56.3% | ||
| Q2 24 | 73.2% | 55.7% | ||
| Q1 24 | 72.8% | 54.6% |
营业利润率PLTKRVTY
| Q4 25 | -41.4% | 14.5% | ||
| Q3 25 | 14.6% | 11.7% | ||
| Q2 25 | 15.8% | 12.6% | ||
| Q1 25 | 9.6% | 10.9% | ||
| Q4 24 | 8.5% | 16.3% | ||
| Q3 24 | 15.7% | 14.3% | ||
| Q2 24 | 22.4% | 12.4% | ||
| Q1 24 | 15.1% | 6.8% |
净利率PLTKRVTY
| Q4 25 | -45.6% | 12.7% | ||
| Q3 25 | 5.8% | 6.7% | ||
| Q2 25 | 4.8% | 7.5% | ||
| Q1 25 | 4.3% | 6.4% | ||
| Q4 24 | -2.6% | 13.0% | ||
| Q3 24 | 6.3% | 13.8% | ||
| Q2 24 | 13.8% | 8.0% | ||
| Q1 24 | 8.1% | 4.0% |
每股收益（稀释后）PLTKRVTY
| Q4 25 | $-0.83 | $0.86 | ||
| Q3 25 | $0.11 | $0.40 | ||
| Q2 25 | $0.09 | $0.46 | ||
| Q1 25 | $0.08 | $0.35 | ||
| Q4 24 | $-0.04 | $0.77 | ||
| Q3 24 | $0.11 | $0.77 | ||
| Q2 24 | $0.23 | $0.45 | ||
| Q1 24 | $0.14 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $684.2M | $919.9M |
| 总债务越低越好 | $2.4B | — |
| 股东权益账面价值 | $-411.4M | $7.3B |
| 总资产 | $3.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLTKRVTY
| Q4 25 | $684.2M | $919.9M | ||
| Q3 25 | $587.9M | $931.4M | ||
| Q2 25 | $500.9M | $991.8M | ||
| Q1 25 | $434.8M | $1.1B | ||
| Q4 24 | $565.8M | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $710.3M | $2.0B | ||
| Q1 24 | $1.0B | $1.7B |
总债务PLTKRVTY
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益PLTKRVTY
| Q4 25 | $-411.4M | $7.3B | ||
| Q3 25 | $-74.8M | $7.4B | ||
| Q2 25 | $-87.8M | $7.6B | ||
| Q1 25 | $-117.2M | $7.6B | ||
| Q4 24 | $-131.1M | $7.7B | ||
| Q3 24 | $-98.0M | $7.9B | ||
| Q2 24 | $-112.9M | $7.9B | ||
| Q1 24 | $-180.4M | $7.8B |
总资产PLTKRVTY
| Q4 25 | $3.7B | $12.2B | ||
| Q3 25 | $3.7B | $12.1B | ||
| Q2 25 | $3.6B | $12.4B | ||
| Q1 25 | $3.6B | $12.4B | ||
| Q4 24 | $3.6B | $12.4B | ||
| Q3 24 | $3.2B | $12.8B | ||
| Q2 24 | $3.2B | $13.4B | ||
| Q1 24 | $3.1B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $285.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $275.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 40.5% | 21.0% |
| 资本支出强度资本支出/营收 | 1.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $531.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PLTKRVTY
| Q4 25 | $285.9M | $182.0M | ||
| Q3 25 | $116.9M | $138.5M | ||
| Q2 25 | $146.1M | $134.3M | ||
| Q1 25 | $18.8M | $128.2M | ||
| Q4 24 | $153.1M | $174.2M | ||
| Q3 24 | $156.9M | $147.9M | ||
| Q2 24 | $150.5M | $158.6M | ||
| Q1 24 | $29.6M | $147.6M |
自由现金流PLTKRVTY
| Q4 25 | $275.2M | $161.8M | ||
| Q3 25 | $106.5M | $120.0M | ||
| Q2 25 | $141.3M | $115.5M | ||
| Q1 25 | $8.4M | $112.2M | ||
| Q4 24 | $140.3M | $149.8M | ||
| Q3 24 | $152.1M | $125.6M | ||
| Q2 24 | $141.2M | $136.6M | ||
| Q1 24 | $15.6M | $129.7M |
自由现金流率PLTKRVTY
| Q4 25 | 40.5% | 21.0% | ||
| Q3 25 | 15.8% | 17.2% | ||
| Q2 25 | 20.3% | 16.0% | ||
| Q1 25 | 1.2% | 16.9% | ||
| Q4 24 | 21.6% | 20.5% | ||
| Q3 24 | 24.5% | 18.4% | ||
| Q2 24 | 22.5% | 19.7% | ||
| Q1 24 | 2.4% | 20.0% |
资本支出强度PLTKRVTY
| Q4 25 | 1.6% | 2.6% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 0.7% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 1.5% | 3.2% | ||
| Q1 24 | 2.1% | 2.7% |
现金转化率PLTKRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.99× | 2.97× | ||
| Q2 25 | 4.40× | 2.49× | ||
| Q1 25 | 0.61× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 3.99× | 1.57× | ||
| Q2 24 | 1.74× | 2.87× | ||
| Q1 24 | 0.56× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLTK
| Third Party Platform | $428.7M | 63% |
| Other | $158.8M | 23% |
| Asia Pacific | $52.7M | 8% |
| Other Geographic Location | $38.6M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
